Generation of anti-FN14 monoclonal antibodies by ex-vivo accelerated antibody evolution
US8609818B2 · kind B2 · utility
2Cited by
0References
38Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 9, 2012 |
| Grant date | Dec 17, 2013 |
| Priority date | — |
| Expiry date | Mar 9, 2032 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/55
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
The present invention relates generally to anti-FN14 antibodies. In particular, the anti-FN14 antibodies described herein are useful for the treatment of diseases, such as a variety of cancers, associated with expression of FN14.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.